ArticleInternational journal of nanomedicine2018
Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity.
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current perspectives and trends in nanoparticle drug delivery systems in breast cancer: bibliometric analysis and review.Frontiers in bioengineering and biotechnology · 2023Pooled it
- Tumor Niche Influences the Activity and Delivery of Anticancer Drugs: Pharmacology Meets Chemistry.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Co-Encapsulation of Multiple Antineoplastic Agents in Liposomes by Exploring Microfluidics.International journal of molecular sciences · 2025Review
- A Hydrogel for Nitric Oxide Sensitization Chemotherapy Mediated by Tumor Microenvironment Changes in 3D Spheroids and Breast Tumor Models.Current pharmaceutical design · 2025Article
- An Updated Insight into Phytomolecules and Novel Approaches used in the Management of Breast Cancer.Current drug targets · 2024Review
- Smart Magnetic Nanocarriers for Codelivery of Nitric Oxide and Doxorubicin for Enhanced Apoptosis in Cancer Cells.ACS omega · 2023Article
- Curcumin I-SMA nanomicelles as promising therapeutic tool to tackle bacterial infections.RSC advances · 2023Article
- Nanoparticle-based delivery systems as emerging therapy in retinoblastoma: recent advances, challenges and prospects.Nanoscale advances · 2023Review
- A technical note on emerging combination approach involved in the onconanotherapeutics.Drug delivery · 2022Review
- Co-Treatment of Caco-2 Cells with Doxorubicin and Gold Nanoparticles Produced fromNanomaterials (Basel, Switzerland) · 2022Article
- Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review).Molecular medicine reports · 2022Review
- Review
- Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review.Current drug metabolism · 2022Review
- Bio-Inspired and Smart Nanoparticles for Triple Negative Breast Cancer Microenvironment.Pharmaceutics · 2021Review
- Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance.Frontiers in molecular biosciences · 2020Review
- Nitric Oxide-Releasing Polymeric Materials for Antimicrobial Applications: A Review.Antioxidants (Basel, Switzerland) · 2019Review
- Controlled Delivery of Nitric Oxide for Cancer Therapy.Pharmaceutical nanotechnology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAnticancer drug delivery systems are often limited by hurdles, such as off-target distribution, slow cellular internalization, limited lysosomal escape, and drug resistance. To overcome these limitations, we have developed a stable nitric oxide (NO)-releasing nanoparticle (polystyrene-maleic acid [SMA]- MATERIALS AND
methodsEffects of SMA-tDodSNO and/or in combination with Dox or SMA-Dox on cell viability, apoptosis, mitochondrial membrane potential, lysosomal membrane permeability, tumor tissue, and tumor growth were studied using in vitro and in vivo model of triple-negative breast cancer (TNBC). In addition, the concentrations of SMA-Dox and Dox in combination with SMA-tDodSNO were measured in cells and tumor tissues.
resultsCombination of SMA-tDodSNO and Dox synergistically decreased cell viability and induced apoptosis in 4T1 (TNBC cells). Incubation of 4T1 cells with SMA-tDodSNO (40 µM) significantly enhanced the cellular uptake of SMA-Dox and increased Dox concentration in the cells resulting in a twofold increase (
conclusionTaken together, these results suggest that SMA-tDodSNO can be used as a successful strategy to increase the efficacy of Dox and SMA-Dox in a model of TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.